-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

473 Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma
Hematology Disease Topics & Pathways:
Research, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, Health outcomes research, B Cell lymphoma, Diseases, Real-world evidence, Aggressive lymphoma, Lymphoid Malignancies
Sunday, December 8, 2024: 10:30 AM

Megan Melody, MD1, Natalie Grover, MD2, Stephanie Franco, MD3, Jason T Romancik, MD4, Matthew J Cortese, MD, MPH5, Tamara K Moyo, MD6*, Rahul S Bhansali, MD7, Thomas Ollila, MD8, Vaishalee P Kenkre, MD9, Lindsey Fitzgerald, MD10, Brian Hess, MD11, Matthew Matasar, MD, MS12, Geoffrey Shouse, PhD, DO13, Kaitlin Annunzio, DO14, Megan M Herr, PhD15, James A Davis, PharmD16*, Christy Jesme, MD10*, Ari Pelcovits, MD17, Jonathan Moreira, MD18, Shuo Ma, MD, PhD18, Jane N Winter, MD19, Adam Yuh Lin, MD PhD18, Alexey Danilov, MD, PhD20, Ishan Roy, MD, PhD21, Stefan K. Barta, MD7, Leo I. Gordon, MD22, Deborah M. Stephens, DO23, Jonathon B Cohen, MD MS24, Narendranath Epperla, MD MS14 and Reem Karmali, MD25

1Feinberg School of Medicine, Northwestern University, Chicago, IL
2University of North Carolina, Chapel Hill, NC
3Feinberg School of Medicine,, Northwestern University, Chicago, IL
4Winship Cancer Institute, Emory University, Atlanta, GA
5Roswell Park Comprehensive Cancer Center, Department of Medicine (Lymphoma Section), Buffalo, NY
6Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC
7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
8Brown University, Providence, RI
9Carbone Cancer Center, University of Wisconsin–Madison, Madison, WI
10Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
11Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
12Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ
13City of Hope Cancer Center, Duarte, CA
14Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH
15Roswell Park Comprehensive Cancer Center, Buffalo, NY
16Division of Hematology-Oncology, Medical University of South Carolina, Charleston, SC
17Rhode Island Hospital, Providence, RI
18Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
19Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
20City of Hope Comprehensive Cancer Center, Duarte, CA
21Shirley Ryan Ability Lab, Chicago, IL
22Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
23University of North Carolina Chapel Hill, Chapel Hill, NC
24Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
25Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

Introduction: Chimeric antigen receptor T-cell therapy (CAR T) achieves durable remissions in 30-40% of patients (pts) with relapsed or refractory B-cell lymphoma (R/R BCL). For those with CAR T failure, few effective therapeutics are available. Although clinical trials with CD3-CD20 bispecific antibodies (BsAbs) in this population have demonstrated CR rates of approximately 40%, only small numbers of pts previously treated with CAR T were included with short follow-up. Furthermore, little is known of real-world practices and efficacy of BsAbs post CART failure.

Methods: In a cohort of 830 pts (pts) with R/R BCL treated with CAR T between 2015 – 2024 across 14 academic institutions, we identified pts treated with BsAbs post CART failure. Wilcoxon rank-sum test and pooled t-test were utilized (two-sided P value of <.05) to determine the statistical significance of differences between variables. Time-to-event curves were estimated using Kaplan-Meier. Cox proportional hazards models were used to determine the impact of clinical variables in pts treated with BsAbs.

Results: 429 pts in our cohort had CART failure. 64 pts were treated with BsAbs at a median of 218 days (range 32-2008) post CAR T failure (30= Epcoritamab, 21=Glofitamab, 7= Mosunetuzumab, and 6= Other) for a median of 4 cycles (4-12). 12 pts (19%) received BsAbs in combination with an adjunctive therapy (6= Revlimid, 2= XRT, 1= Zanubrutinib, 1= BV, 1= Polatuzumab, 1= Azacitidine). Clinical characteristics at time of BsAb administration included median age of 62 years (range 24-84), 59% male, 73% Caucasians, 17% African American, 39% with primary refractory disease with frontline therapy (PRD), 70% with DLBCL followed by 6% with tFL, 19% with double hit (DHL), and 30% with double expressor (DEL) lymphoma.

Overall response rate (ORR) to BsAbs post CAR T was 54% (29/54 evaluable pts) with a CR rate of 33% (18/54). At a median follow-up of 400 days (d) after initiation of BsAbs, 66.7% pts remained in CR. 23.4% (15/64) developed grade 1-2 cytokine release syndrome (CRS) with BsAbs; no pts developed grade 3 CRS. 4 pts developed grade 1 neurotoxicity (NT); no pts developed higher grade NT. 6 pts received tocilizumab and 7 pts received steroids for CRS.

Median PFS (mPFS) and median OS (mOS) for pts treated with BsAbs were 145 and 227 d respectively. After BsAbs failure, mOS was 75 d. Prior bendamustine exposure, use of adjunctive therapy with BsAbs, BsAbs construct, onset of CRS or use of steroids for toxicity management with BsAbs, did not impact PFS and OS with BsAbs treatment. Elevated LDH at time of BsAb administration impacted PFS (85 d vs NR, p =0.01), but not OS. Pts who developed NT had decreased mOS as compared to pts without NT (75 vs 532 d, p = 0.007). Pts with DHL (n= 11, 17%) vs non-DHL had inferior mPFS (80 d vs 168 d, p = 0.06) and significantly inferior mOS (115 vs 654 d, p =0.01). Pts with PRD vs not had both inferior mPFS (85 days vs 184 days, p = 0.05) and mOS (161 days vs 532 days, p < 0.05). 45% (29/64) of pts received BsAbs as first line salvage post CAR T and had improved mPFS when compared to those who received BsAbs ≥ 2nd line post CART (148 vs 103 d, p = 0.07); however, there was no difference in mOS between these two groups (p=0.2). Although there was no difference in ORR or CR between pts who experienced early (< 90 days post) vs late (> 90 days) post CART failure/relapse, mOS was markedly reduced in pts with early relapse vs late relapse post CART (150 vs 1045 d, p=0.02).

In a multivariable analysis, inferior PFS was associated with elevated LDH (HR 9.0, 95% CI 3.0-36.4) and bulky disease (HR 4.4, 95% CI 1.7-11.6). Inferior OS was associated with DHL (HR 3.0, 95% CI 1.04-8.4), elevated LDH at time of BsAbs treatment (HR 3.3, 95% CI 1.1 – 9.5), early CART failure/relapse (HR 2.8 95% CI 1.1-7.0).

Conclusions: In this large real-world multi-center cohort of pts treated with BsAbs after CAR T failure, response rates and survival were diminished as compared to results previously reported in clinical trials. Although there did not appear to be a benefit to the concurrent administration of additional therapies with BsAbs, the small sample size of this pt subset limits interpretability. In pts with prior CAR T, elevated LDH, DHL, and early CART failure within 90 days appear to be negative predictors of survival for treatment with BsAbs with dismal outcomes after BsAb failure. These pt subsets should be prioritized for clinical trials evaluating alternative novel therapies.

Disclosures: Grover: ADC Therapeutics: Honoraria; Regeneron: Honoraria, Research Funding; Seagen: Honoraria; Novartis: Honoraria; Ono Pharma: Honoraria; BMS: Honoraria, Research Funding; Caribou: Honoraria; Genentech: Honoraria; Cabaletta: Research Funding; Janssen: Honoraria; Kite: Honoraria; Sangamo: Current holder of stock options in a privately-held company. Romancik: Astra Zeneca: Consultancy; ADC Therapeutics: Consultancy; Kite: Consultancy. Moyo: J&J: Research Funding; Genmab: Research Funding; Kite Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Century Therapeutics: Research Funding. Ollila: ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Ono Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Lilly: Research Funding. Kenkre: Ipsen: Research Funding. Matasar: Roche: Consultancy, Honoraria, Research Funding; Allogene: Membership on an entity's Board of Directors or advisory committees; Kite: Honoraria; Genentech: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Genmab: Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria; Epizyme: Honoraria; GM Biosciences: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Johnson & Johnson: Consultancy, Honoraria, Research Funding; IMV Therapeutics: Honoraria; Merck: Current equity holder in publicly-traded company; Regeneron Pharmaceuticals, Inc.: Honoraria; BMS/Celgene: Honoraria; Immunovaccine Technologies: Research Funding; ADC Therapeutics: Honoraria; AstraZeneca: Honoraria; Bayer: Consultancy, Honoraria, Research Funding. Shouse: Astra Zeneca: Honoraria; Abbvie: Consultancy; Kite Pharmaceuticals: Consultancy, Honoraria, Speakers Bureau; Beigene, Inc: Consultancy, Honoraria, Speakers Bureau. Davis: Janssen Biotech: Speakers Bureau. Ma: AstraZeneca: Consultancy, Research Funding, Speakers Bureau; BeiGene: Consultancy, Research Funding, Speakers Bureau; Lilly: Research Funding, Speakers Bureau; Janssen: Consultancy; Juno: Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. Winter: Merck: Consultancy, Research Funding; BMS: Consultancy; Genetech: Consultancy. Lin: Genmab: Honoraria, Speakers Bureau; Abbvie: Honoraria, Speakers Bureau. Danilov: Janssen: Consultancy; GenMab: Consultancy, Research Funding; Cyclacel: Research Funding; Bristol Meyers Squibb: Consultancy, Research Funding; ADCT: Consultancy; MEI Pharma: Research Funding; Takeda: Research Funding; Bayer: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Incyte: Consultancy; MorphoSys: Consultancy; Nurix: Consultancy, Research Funding; Genentech: Consultancy; BeiGene: Consultancy; AbbVie: Consultancy; AstraZeneca: Consultancy, Research Funding. Barta: Acrotech: Consultancy; BMS: Consultancy; Kyowa Kirin: Consultancy; Janssen: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy. Gordon: Bristol Meyers Squibb, Kite Pharmaceuticals: Other: Advisory board; Ono Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; nanoparticles for cancer therapy (HDL NP As Inducers of Ferroptosis in Cancer, PCT/US2020/051549; b) Nanostructures for Treating Cancer and Other Conditions, PCT/UlllllLS2013/027431): Patents & Royalties: nanoparticles for cancer therapy (HDL NP As Inducers of Ferroptosis in Cancer, PCT/US2020/051549; b) Nanostructures for Treating Cancer and Other Conditions, PCT/UlllllLS2013/027431); Janssen: Other: data and safety monitoring board . Stephens: AstraZeneca, Beigene, Novartis: Research Funding; Abbvie, AstraZeneca, Beigene, BMS, Celegene, Eli Lilly, Genentech, Janssen, Pharmacyclics: Consultancy. Epperla: BeiGene: Research Funding, Speakers Bureau; Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte Corporation: Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genentech: Speakers Bureau; ADC Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Research Funding. Karmali: Genmab: Honoraria; Ipsen: Speakers Bureau; Genentech/Roche: Honoraria; BeiGene: Speakers Bureau; AstraZeneca: Speakers Bureau; Incyte: Speakers Bureau; Abbvie: Honoraria; BMS: Honoraria.

*signifies non-member of ASH